|
|
||||||||
Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
Correspondence
William E. Miller
william.miller{at}uc.edu
| ABSTRACT |
|---|
|
|
|---|
N). Infection with the FLAG–US28/R129A virus failed to induce inositol phosphate accumulation, indicating that G-protein coupling is essential for pUS28 signalling to phospholipase C-β (PLC-β) during HCMV infection. The FLAG–US28/
N virus induced about 80 % of the level of PLC-β signalling induced by the FLAG–US28/WT virus, demonstrating that the N-terminal chemokine-binding domain is not required for pUS28-induced PLC-β signalling in infected cells. The data presented here are the first to describe the functional analyses of several key pUS28 mutants in HCMV-infected cells. Elucidating the mechanisms by which pUS28 signals during infection will provide important insights into HCMV pathogenesis. | INTRODUCTION |
|---|
|
|
|---|
pUS28 exhibits significant signalling activity, including the ability to activate the phospholipase C-β (PLC-β), the tyrosine kinase c-Src and the small G protein RhoA (Billstrom et al., 1998
; Casarosa et al., 2001
; Gao & Murphy, 1994
; McLean et al., 2004
; Melnychuk et al., 2004
; Minisini et al., 2003
; Streblow et al., 2003
; Waldhoer et al., 2002
). pUS28 shares significant homology to C-C chemokine receptors and, accordingly, can bind C-C chemokines, including CCL5/RANTES, CCL2/MCP-1 and CCL4/MIP-1β (Bodaghi et al., 1998
; Kledal et al., 1998
; Kuhn et al., 1995
; Neote et al., 1993
). Interaction of C-C chemokines with pUS28 requires the presence of a 6 aa segment between amino acids 11 and 16, as pUS28 mutants deleted for this region are unable to bind chemokine (Casarosa et al., 2005
). Although these chemokines bind with high affinity to pUS28, their roles in signalling remain unclear as some pUS28 signalling pathways appear to be chemokine-dependent, while others appear to be chemokine-independent (Billstrom et al., 1998
; Casarosa et al., 2001
; Melnychuk et al., 2004
; Minisini et al., 2003
; Streblow et al., 2003
). HCMV-infected cells secrete CCL5/RANTES and CCL2/MCP-1, which further complicates issues regarding chemokines and pUS28 signalling activity, as the secreted chemokines could bind to pUS28 and activate it in an autocrine manner (Bodaghi et al., 1998
; Michelson et al., 1997
; Randolph-Habecker et al., 2002
; Taylor & Bresnahan, 2006
). Thus, it remains unclear if the chemokine-independent signalling activity exhibited by pUS28 in HCMV-infected cells is truly due to pUS28 alone or is the result of an interaction between pUS28 and a secreted chemokine.
The current understanding of the pUS28 domains required for signalling comes from studies using transient overexpression systems to express pUS28 mutants (Casarosa et al., 2003
, 2005
; Miller et al., 2003
; Mokros et al., 2002
; Waldhoer et al., 2003
). pUS28 activity has therefore been assessed by overexpressing pUS28 mutants in the absence of an HCMV infection. However, pUS28 activity may be influenced by viral or cellular gene products (e.g. host cell chemokines) expressed in HCMV-infected cells (Bodaghi et al., 1998
; Michelson et al., 1997
; Randolph-Habecker et al., 2002
; Streblow et al., 1999
). Additionally, it is still unclear how the expression levels of pUS28 in many heterologous systems compare with those in HCMV-infected cells and could represent non-physiological levels of pUS28 expression. It is now appreciated that overexpression of signalling proteins has led to spurious conclusions about their functions; it is therefore important to study the effects of pUS28 mutations at physiologically relevant cellular concentrations.
The experiments reported here use HCMV viral recombinants expressing mutant pUS28 proteins to investigate the role of G-protein coupling (using the FLAG–US28/R129A recombinant virus) and chemokine-binding (using the FLAG–US28/
N recombinant virus) in pUS28-mediated signal transduction in HCMV-infected cells.
| METHODS |
|---|
|
|
|---|
Construction of HCMV US28 recombinants.
Recombineering at the US28 locus was performed using the red recombinase plasmid pKD46 and the Flp recombinase plasmid pCP20 as described previously (Datsenko & Wanner, 2000
). Escherichia coli harbouring HCMV FIX-BAC (bacterial artificial chromosome) was obtained from G. Hahn (Hahn et al., 2002
). For
US28 FIX-BAC, PCR primers with homology to the UTRs of US28 were used to amplify an FLP recognition target (FRT)-flanked kanamycin (Kan) resistance gene, the PCR fragment was recombined into parental FIX-BAC and screened for recombination by growth in Kan. For FLAG–US28/
N FIX-BAC, the Kan cassette was first removed from
US28 FIX-BAC using the Flp recombinase. Primers with homology to untranslated regions (UTRs) of US28 were then used to amplify FLAG–US28/
N, with an FRT–KAN–FRT cassette following the stop codon, and this PCR fragment was recombined into
US28 FIX-BAC. Recombination was screened by growth in Kan and the FRT–KAN–FRT cassette was later removed using the Flp recombinase. For FLAG–US28/WT and FLAG–US28/R129A, BACs were manipulated using a two-step method. In step one, PCR primers with homology to the UTRs of the US28 were used to amplify a cassette containing a Kan resistance gene and LacZ fragment which was then recombined into FIX-BAC to knockout US28. Recombinants were selected based on Kan resistance and blue colour upon exposure to X-Gal. In the second step, PCR products containing FLAG–US28/WT or FLAG–US28/R129A were recombined into the US28 locus, removing the Kan/LacZ cassette. Recombinants were selected by Kan sensitivity and white colour when plated on X-Gal-containing medium. Two independent recombinant BACs were made for each mutant used in this study. Recombination at the US28 locus was verified by PCR of BAC DNA isolated from E. coli using a standard mini-prep and amplified using primer sets with homology external to the site of recombination at the US28 locus, within the FLAG sequence or the UL146 gene. The sequences of each recombinant, including the US28 locus and regions surrounding the recombination site, were confirmed by automated ABI DNA sequencing (University of Cincinnati). For reconstitution of recombinant viruses, 2x105 MRC-5 cells were plated in six-well plates and transfected with 2 µg FIX-BAC DNAs using either SuperFect (Qiagen) or Transit IT (Mirus) lipid transfection reagents according to the manufacturer's protocol. Ten days post-transfection, MRC-5 cells were transferred to T-25 flasks and fed with fresh medium every 3–4 days. After the appearance of virus-associated cytopathic effects (CPE), infected MRC-5 cells were mixed with uninfected HFFs and cultured until the CPE reached 100 %. Supernatants containing recombinant viruses were used for the generation of virus stocks.
Inositol phosphate accumulation.
HFFs were seeded in 12-well plates at a density of 1.5x105 cells per well and either mock-infected or infected with HCMV recombinants at an m.o.i. of 0.03, 0.1, 0.3, 1 or 3. Twenty-four hours post-infection, virus-containing medium was removed and replaced with serum-free modified Eagle's medium (MEM; Mediatech) containing 1 µCi ml–1 (74 kBq ml–1) of [3H]myoinositol (PerkinElmer Life Sciences). Forty-eight hours post-infection, medium was removed and replaced with serum-free medium containing 20 mM LiCl for 2 h. Reactions were stopped by aspirating medium, adding 1 ml of 0.4 M perchloric acid, and cooling undisturbed at 4 °C for 5 min. Supernatant (800 µl) was neutralized with 400 µl of 0.72 M KOH/0.6 M KHCO3 and subjected to centrifugation. Supernatant (1 ml) was diluted with 3 ml distilled H2O and applied to freshly prepared Dowex columns (AG1-X8; Bio-Rad). Columns were washed two times with distilled H2O; total inositol phosphates were eluted with 4.0 ml of 0.1 M formic acid, 1 M ammonium formate and eluates containing accumulated inositol phosphates were counted in a liquid scintillation counter. Neutralized supernatant (50 µl) was counted in a liquid scintillation counter to measure total incorporated [3H]myoinositol. Data are expressed as accumulated inositol phosphate over total incorporated [3H]myoinositol.
Immunoprecipitation and Western blotting.
HFFs were seeded in 100 mm dishes at a density of 2.0x106 cells per plate and either mock-infected or infected with HCMV recombinants at an m.o.i. of 3. Forty-eight hours post-infection, cells were lysed in 1 ml RIPA buffer [150 mM NaCl, 10 mM Tris, 5 mM EDTA, 0.1 % SDS, 1.0 % DOC, 1.0 % Triton X-100 and Complete protease inhibitors (Roche)]. Clarified lysate was saved as whole-cell extracts (50 µl) or incubated with anti-FLAG M2-agarose beads (Sigma) to immunoprecipitate pFLAG–US28 proteins. Beads were washed twice with lysis buffer and eluted using 50 µl Laemmli sample buffer. Whole-cell extracts or FLAG immunoprecipitates were separated by SDS-PAGE and subjected to Western blotting using antibodies directed against the FLAG epitope (sc-805; Santa Cruz), HCMV IE proteins (MAB810; Chemicon) or HCMV pUL44 (a kind gift from John D. Shanley, University of Connecticut, CT). Reactive proteins were detected using the appropriate secondary antibodies in an enhanced chemiluminescence system (ECL; Amersham Biosciences).
Radioligand binding.
HFFs were seeded in 12-well plates at a density of 1.5x105 cells per well and either mock-infected or infected with HCMV recombinants at an m.o.i. of 3. Forty-eight hours post-infection, cells were pre-incubated in the absence or presence of 14 nM unlabelled CCL5/RANTES for 15 min in ice-cold binding buffer (50 mM HEPES, 1 mM CaCl2, 5 mM MgCl2 and 0.5 % BSA). 125I-labelled CCL5/RANTES (Perkin Elmer) was then added to a final concentration of 28 pM and incubated for 3 h at 4 °C. Cells were washed three times in ice-cold binding buffer supplemented with 500 mM NaCl, lysed in 500 mM NaOH and specific binding was evaluated using a liquid scintillation counter.
FACS analysis of cell surface expression.
HFFs were seeded in 12-well plates at a density of 1.5x105 cells per well and either mock-infected or infected with HCMV recombinants at an m.o.i. of 3. Forty-eight hours post-infection, cells were dislodged by trypsinization, washed twice in ice-cold PBS and stained for 2 h at 4 °C in M2-biotin (Sigma) diluted 1 : 100 in FACS staining buffer (PBS supplemented with 0.5 % BSA). Cells were washed twice with ice-cold PBS and stained for 2 h at 4 °C in streptavidin-phycoerythrin (PE) (BD biosciences) diluted 1 : 100 in FACS staining buffer. Cells were washed twice with ice-cold PBS and analysed using the FL2 channel on a FACSCalibur flow cytometer (BD Biosciences).
| RESULTS |
|---|
|
|
|---|
N mutant viruses
US28, FLAG–US28/WT, FLAG–US28/R129A and FLAG–US28/
N recombinant viruses. pUS28/R129A and pUS28/
N mutants are particularly informative as transient overexpression studies demonstrate that they fail to activate G-proteins and bind chemokines, respectively. US28 was knocked out by inserting an FRT–Kan–FRT cassette into the US28 locus, creating
US28 FIX-BAC (Fig. 1
N FIX-BAC, which lacks amino acids 2–16 (Fig. 1
|
|
N expression and chemokine binding in HCMV-infected cells
N in HCMV-infected cells. The incorporation of the N-terminal FLAG epitope into pUS28 allows us to easily analyse the kinetics of US28 expression and enables us to determine if mutant proteins such as pFLAG–US28/R129A and pFLAG–US28/
N are expressed at levels equivalent to pFLAG–US28/WT. There is some discrepancy in the literature regarding the kinetics of US28 expression, as RT-PCR analyses suggest that it may be expressed as early as 4 h post-infection, while Northern and Western blot analyses suggest that US28 is expressed beginning 24 and 48 h post-infection (Bodaghi et al., 1998
|
N is expressed at a similar level but runs at a lower molecular mass. pFLAG–US28/
N was expected to migrate faster since it is deleted for amino acids 2–16. Surprisingly, pFLAG–US28/WT and pFLAG–US28/R129A appear as doublets, while pFLAG–US28/
N migrates as a single band. This suggests that pUS28 may be post-translationally modified at the amino terminus, or that the pUS28 amino terminus is required for modification somewhere else in the protein. This was not examined further, but may be the result of O-linked glycosylation, as proposed by Casarosa et al. (2005)
|
US28 virus exhibited negligible amounts of [125I]CCL5/RANTES binding, while cells infected with FLAG–US28/WT virus exhibited chemokine-binding equivalent to the parental HCMV-FIX virus (Fig. 4b
N virus were completely defective in [125I]CCL5/RANTES binding. Importantly, the results with the pFLAG–US28/
N mutant in HCMV-infected cells are consistent with ligand binding experiments performed in transfected cells expressing pUS28/
N and indicate that amino acids 2–16 of pUS28 play an essential role in chemokine binding (Casarosa et al., 2003
We next sought to investigate the ability of the pUS28 mutants to accumulate on the cell surface in HCMV-infected HFFs. Although pUS28 undergoes constitutive internalization and is largely localized to intracellular vesicles, we are able to detect cell surface expression of pFLAG–US28/WT using anti-FLAG antibodies in FACS experiments (Fig. 4c
, upper panel). pFLAG–US28/R129A exhibited similar levels of cell surface expression (116±22 %) in comparison with pFLAG–US28/WT (Fig. 4c
, middle panel). pFLAG–US28/
N, however, was partially defective in its ability to accumulate on the cell surface (16±5 %) in comparison with pFLAG–US28/WT (Fig. 4c
, lower panel). Since pUS28 does undergo constitutive internalization, it is unclear if the decreased cell surface expression of pFLAG–US28/
N is due to faster internalization kinetics or perhaps becomes partially trapped as it traffics to the plasma membrane.
pUS28 signalling to PLC-β in HCMV-infected cells requires G-protein coupling, but not chemokine binding
pUS28 is a potent activator of PLC-β, resulting in high levels of inositol phosphate (InsP) accumulation; however, the domains in pUS28 required for this activity in HCMV-infected cells remain unknown.
Therefore, we utilized the HCMV-FIX US28 recombinant viruses to address issues regarding the influence of G-protein coupling and chemokine binding on pUS28-stimulated PLC-β signalling in HCMV-infected cells. HFFs were uninfected or infected at various m.o.i. with the parental HCMV-FIX or with the FLAG–US28/WT recombinant and PLC-β signalling was assessed at 48 h post-infection by measuring the accumulation of total inositol phosphates (InsP). The FLAG–US28/WT recombinant exhibited a dose-dependent induction of InsP accumulation indistinguishable from that of the parental virus (Fig. 5a
). This indicated that the N-terminal FLAG epitope did not affect pUS28 signalling and we therefore utilized the FLAG–US28/WT recombinant as the control virus for all subsequent experiments. We also compared signalling in
US28-infected cells with FLAG–US28/WT-infected cells (Fig. 5b
) and, similar to the results of Minisini et al. (2003)
, we observed no InsP accumulation with the
US28 virus. These data confirm that the InsP signalling we observe in HCMV-FIX-infected cells is solely due to pUS28 and provides the basis for our analyses of InsP signalling induced by the pFLAG–US28 mutants.
|
subunit of the heterotrimeric complex, and thus is critical for GPCR-mediated signalling. This highly conserved motif is present in many of the herpesviral GPCRs, including pUS28, and is necessary for pUS28 signalling to PLC-β in transfected cells (Pleskoff et al., 2005
US28 infection at each m.o.i. tested (P<0.05). These results indicate that this conserved DRY motif is critical for pUS28 activation of PLC-β signalling in infected cells and indicate that pUS28 action is mediated by traditional, G protein-dependent events.
|
N recombinant virus provides an important reagent to directly examine the potential effects of chemokine binding on pUS28 signalling activity. HFFs were uninfected or infected with the FLAG–US28/
N virus and signalling was compared with cells infected with the FLAG–US28/WT virus at 48 h post-infection (Fig. 6b
N virus exhibited 43 % of the InsP accumulation induced by the FLAG–US28/WT virus at an m.o.i. of 0.03 (P<0.05) and 78 % of the InsP accumulation induced by the FLAG–US28/WT virus at an m.o.i. of 3.0 (P<0.05). These results indicate that, in infected cells, chemokine binding to pUS28 is not required for high levels of pUS28-stimulated signalling through the PLC-β pathway. | DISCUSSION |
|---|
|
|
|---|
Our analysis of pUS28 wild-type and mutant proteins during HCMV infection allows us to correlate many important biological properties, including PLC-β signalling, chemokine binding and localization to the plasma membrane. Cells infected with the FLAG–US28/R129A virus failed to signal through PLC-β and bound 51 % of the CCL5/RANTES in comparison with the FLAG–US28/WT virus. FACS analysis revealed that pFLAG–US28/R129A and pFLAG–US28/WT are similarly expressed on the plasma membrane, indicating that both proteins should equally be exposed to chemokine. The modest decrease in chemokine binding observed in FLAG–US28/R129A-infected cells is likely due to a conformational change in pUS28/R129A, which alters the ligand affinity as has been observed for several GPCRs with mutations in their DRY box (Bennett et al., 2000
; Chung et al., 2002
; Rhee et al., 2000
). pFLAG–US28/
N signalling to PLB-β remains quite robust (78 % compared with pFLAG–US28/WT at an m.o.i. of 3.0). However, pFLAG–US28/
N was completely defective in CCL5/RANTES binding, which is expected from studies reported in Casarosa et al. (2005)
. Interestingly, pFLAG–US28/
N is partially defective in its steady-state cell-surface expression in comparison with pFLAG–US28/WT. Therefore, we attribute the slight defect in pFLAG–US28/
N-induced PLC-β signalling to the reduced steady state levels of pFLAG–US28/
N compared with pFLAG–US28/WT.
The ability of pUS28 to signal so potently through PLC-β in the absence of chemokine binding is an important diversion from events occurring with most cellular GPCRs. While there are several reports of agonist independent signalling for cellular receptors, this signalling is usually far more conservative than that exhibited by pUS28 (Carroll et al., 2001
; Quitterer et al., 1996
; Seifert & Wenzel-Seifert, 2002
). Although pUS28-dependent PLC-β signalling does not require chemokine-binding, several other pUS28-dependent signalling pathways, including RhoA and c-Src, do appear to require chemokine (Melnychuk et al., 2004
; Minisini et al., 2003
; Streblow et al., 2003
). Our mutants will be particularly interesting in future studies aimed at understanding how pUS28 activates molecules such as RhoA and c-Src on a more mechanistic level. It is tempting to speculate that pUS28 may be coupled to Gq/PLC-β in a chemokine-independent manner and then switch to G12/RhoA in the presence of chemokine.
HCMV recombinants expressing mutant pUS28 proteins will allow us to continue to investigate pUS28 signalling in the context of viral infection and will facilitate the analyses of biological activities of pUS28 including cellular proliferation and migration.
| ACKNOWLEDGEMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
Bennett, T. A., Maestas, D. C. & Prossnitz, E. R. (2000). Arrestin binding to the G protein-coupled N-formyl peptide receptor is regulated by the conserved "DRY" sequence. J Biol Chem 275, 24590–24594.
Billstrom, M. A., Johnson, G. L., Avdi, N. J. & Worthen, G. S. (1998). Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection. J Virol 72, 5535–5544.
Bodaghi, B., Jones, T. R., Zipeto, D., Vita, C., Sun, L., Laurent, L., Arenzana-Seisdedos, F., Virelizier, J. L. & Michelson, S. (1998). Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J Exp Med 188, 855–866.
Boomker, J. M., Verschuuren, E. A., Brinker, M. G., de Leij, L. F., The, T. H. & Harmsen, M. C. (2006). Kinetics of US28 gene expression during active human cytomegalovirus infection in lung-transplant recipients. J Infect Dis 193, 1552–1556.[CrossRef][Medline]
Borst, E. M., Hahn, G., Koszinowski, U. H. & Messerle, M. (1999). Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73, 8320–8329.
Britt, W. J., Jarvis, M., Seo, J. Y., Drummond, D. & Nelson, J. (2004). Rapid genetic engineering of human cytomegalovirus by using a lambda phage linear recombination system: demonstration that pp28 (UL99) is essential for production of infectious virus. J Virol 78, 539–543.
Browne, H., Churcher, M. & Minson, A. (1992). Identification, characterization and deletion analysis of HCMV gene products with homology to G protein-coupled receptors. The Seventeenth Annual International Herpesvirus Workshop 275.
Carroll, F. Y., Stolle, A., Beart, P. M., Voerste, A., Brabet, I., Mauler, F., Joly, C., Antonicek, H., Bockaert, J. & other authors (2001). BAY36–7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 59, 965–973.
Casarosa, P., Bakker, R. A., Verzijl, D., Navis, M., Timmerman, H., Leurs, R. & Smit, M. J. (2001). Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J Biol Chem 276, 1133–1137.
Casarosa, P., Menge, W. M., Minisini, R., Otto, C., van Heteren, J., Jongejan, A., Timmerman, H., Moepps, B., Kirchhoff, F. & other authors (2003). Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor. J Biol Chem 278, 5172–5178.
Casarosa, P., Waldhoer, M., LiWang, P. J., Vischer, H. F., Kledal, T., Timmerman, H., Schwartz, T. W., Smit, M. J. & Leurs, R. (2005). CC and CX3C chemokines differentially interact with the N terminus of the human cytomegalovirus-encoded US28 receptor. J Biol Chem 280, 3275–3285.
Chee, M. S., Satchwell, S. C., Preddie, E., Weston, K. M. & Barrell, B. G. (1990). Human cytomegalovirus encodes three G protein-coupled receptor homologues. Nature 344, 774–777.[CrossRef][Medline]
Chung, D. A., Wade, S. M., Fowler, C. B., Woods, D. D., Abada, P. B., Mosberg, H. I. & Neubig, R. R. (2002). Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors. Biochem Biophys Res Commun 293, 1233–1241.[CrossRef][Medline]
Datsenko, K. A. & Wanner, B. L. (2000). One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97, 6640–6645.
Davis-Poynter, N. J., Lynch, D. M., Vally, H., Shellam, G. R., Rawlinson, W. D., Barrell, B. G. & Farrell, H. E. (1997). Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus. J Virol 71, 1521–1529.[Abstract]
Gao, J. L. & Murphy, P. M. (1994). Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J Biol Chem 269, 28539–28542.
Hahn, G., Khan, H., Baldanti, F., Koszinowski, U. H., Revello, M. G. & Gerna, G. (2002). The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J Virol 76, 9551–9555.
Kledal, T. N., Rosenkilde, M. M. & Schwartz, T. W. (1998). Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28. FEBS Lett 441, 209–214.[CrossRef][Medline]
Kuhn, D. E., Beall, C. J. & Kolattukudy, P. E. (1995). The cytomegalovirus US28 protein binds multiple CC chemokines with high affinity. Biochem Biophys Res Commun 211, 325–330.[CrossRef][Medline]
Loh, L. C., Keeler, V. D. & Shanley, J. D. (1999). Sequence requirements for the nuclear localization of the murine cytomegalovirus M44 gene product pp50. Virology 259, 43–59.[CrossRef][Medline]
Maussang, D., Verzijl, D., van Walsum, M., Leurs, R., Holl, J., Pleskoff, O., Michel, D., van Dongen, G. A. & Smit, M. J. (2006). Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci U S A 103, 13068–13073.
McLean, K. A., Holst, P. J., Martini, L., Schwartz, T. W. & Rosenkilde, M. M. (2004). Similar activation of signal transduction pathways by the herpesvirus-encoded chemokine receptors US28 and ORF74. Virology 325, 241–251.[CrossRef][Medline]
Melnychuk, R. M., Streblow, D. N., Smith, P. P., Hirsch, A. J., Pancheva, D. & Nelson, J. A. (2004). Human cytomegalovirus-encoded G protein-coupled receptor US28 mediates smooth muscle cell migration through G
12. J Virol 78, 8382–8391.
Michelson, S., Dal Monte, P., Zipeto, D., Bodaghi, B., Laurent, L., Oberlin, E., Arenzana-Seisdedos, F., Virelizier, J. L. & Landini, M. P. (1997). Modulation of RANTES production by human cytomegalovirus infection of fibroblasts. J Virol 71, 6495–6500.[Abstract]
Miller, W. E., Houtz, D. A., Nelson, C. D., Kolattukudy, P. E. & Lefkowitz, R. J. (2003). G-protein-coupled receptor (GPCR) kinase phosphorylation and beta-arrestin recruitment regulate the constitutive signaling activity of the human cytomegalovirus US28 GPCR. J Biol Chem 278, 21663–21671.
Minisini, R., Tulone, C., Luske, A., Michel, D., Mertens, T., Gierschik, P. & Moepps, B. (2003). Constitutive inositol phosphate formation in cytomegalovirus-infected human fibroblasts is due to expression of the chemokine receptor homologue pUS28. J Virol 77, 4489–4501.
Mokros, T., Rehm, A., Droese, J., Oppermann, M., Lipp, M. & Hopken, U. E. (2002). Surface expression and endocytosis of the human cytomegalovirus-encoded chemokine receptor US28 is regulated by agonist-independent phosphorylation. J Biol Chem 277, 45122–45128.
Neote, K., DiGregorio, D., Mak, J. Y., Horuk, R. & Schall, T. J. (1993). Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 72, 415–425.[CrossRef][Medline]
Oppenheim, A. B., Rattray, A. J., Bubunenko, M., Thomason, L. C. & Court, D. L. (2004). In vivo recombineering of bacteriophage
by PCR fragments and single-strand oligonucleotides. Virology 319, 185–189.[CrossRef][Medline]
Pleskoff, O., Casarosa, P., Verneuil, L., Ainoun, F., Beisser, P., Smit, M., Leurs, R., Schneider, P., Michelson, S. & Ameisen, J. C. (2005). The human cytomegalovirus-encoded chemokine receptor US28 induces caspase-dependent apoptosis. FEBS J 272, 4163–4177.[CrossRef][Medline]
Quitterer, U., AbdAlla, S., Jarnagin, K. & Müller-Esterl, W. (1996). Na+ ions binding to the bradykinin B2 receptor suppress agonist-independent receptor activation. Biochemistry 35, 13368–13377.[CrossRef][Medline]
Randolph-Habecker, J. R., Rahill, B., Torok-Storb, B., Vieira, J., Kolattukudy, P. E., Rovin, B. H. & Sedmak, D. D. (2002). The expression of the cytomegalovirus chemokine receptor homolog US28 sequesters biologically active CC chemokines and alters IL-8 production. Cytokine 19, 37–46.[Medline]
Rhee, M. H., Nevo, I., Levy, R. & Vogel, Z. (2000). Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of the CB2 cannabinoid receptor. FEBS Lett 466, 300–304.[CrossRef][Medline]
Rigoutsos, I., Novotny, J., Huynh, T., Chin-Bow, S. T., Parida, L., Platt, D., Coleman, D. & Shenk, T. (2003). In silico pattern-based analysis of the human cytomegalovirus genome. J Virol 77, 4326–4344.
Seifert, R. & Wenzel-Seifert, K. (2002). Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366, 381–416.[CrossRef][Medline]
Streblow, D. N., Soderberg-Naucler, C., Vieira, J., Smith, P., Wakabayashi, E., Ruchti, F., Mattison, K., Altschuler, Y. & Nelson, J. A. (1999). The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99, 511–520.[CrossRef][Medline]
Streblow, D. N., Vomaske, J., Smith, P., Melnychuk, R., Hall, L., Pancheva, D., Smit, M., Casarosa, P., Schlaepfer, D. D. & Nelson, J. A. (2003). Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src. J Biol Chem 278, 50456–50465.
Taylor, R. T. & Bresnahan, W. A. (2006). Human cytomegalovirus immediate-early 2 protein IE86 blocks virus-induced chemokine expression. J Virol 80, 920–928.
Vieira, J., Schall, T. J., Corey, L. & Geballe, A. P. (1998). Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene. J Virol 72, 8158–8165.
Wagner, M. & Koszinowski, U. H. (2004). Mutagenesis of viral BACs with linear PCR fragments (ET recombination). Methods Mol Biol 256, 257–268.[Medline]
Waldhoer, M., Kledal, T. N., Farrell, H. & Schwartz, T. W. (2002). Murine cytomegalovirus (CMV) M33 and human CMV US28 receptors exhibit similar constitutive signaling activities. J Virol 76, 8161–8168.
Waldhoer, M., Casarosa, P., Rosenkilde, M. M., Smit, M. J., Leurs, R., Whistler, J. L. & Schwartz, T. W. (2003). The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by mediating constitutive endocytosis. J Biol Chem 278, 19473–19482.
Welch, A. R., McGregor, L. M. & Gibson, W. (1991). Cytomegalovirus homologs of cellular G protein-coupled receptor genes are transcribed. J Virol 65, 3915–3918.
Zipeto, D., Bodaghi, B., Laurent, L., Virelizier, J. L. & Michelson, S. (1999). Kinetics of transcription of human cytomegalovirus chemokine receptor US28 in different cell types. J Gen Virol 80, 543–547.[Abstract]
Received 8 June 2007;
accepted 23 September 2007.
This article has been cited by other articles:
![]() |
M. P. Stropes, O. D. Schneider, W. A. Zagorski, J. L. C. Miller, and W. E. Miller The Carboxy-Terminal Tail of Human Cytomegalovirus (HCMV) US28 Regulates both Chemokine-Independent and Chemokine-Dependent Signaling in HCMV-Infected Cells J. Virol., October 1, 2009; 83(19): 10016 - 10027. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Sherrill, M. P. Stropes, O. D. Schneider, D. E. Koch, F. M. Bittencourt, J. L. C. Miller, and W. E. Miller Activation of Intracellular Signaling Pathways by the Murine Cytomegalovirus G Protein-Coupled Receptor M33 Occurs via PLC-{beta}/PKC-Dependent and -Independent Mechanisms J. Virol., August 15, 2009; 83(16): 8141 - 8152. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |